West Pharmaceuticals Lifts Full-Year Forecast as Obesity and Diabetes Device Sales Surge
West Pharmaceuticals (WST) raises its 2025 outlook after strong demand for self-injection devices drives revenue and profit above expectations.
/ 926 items
#Healthcare↓
Innate Pharma Receives Strong Buy Recommendation for Cancer Drug Potential
Innate Pharma got a "Buy" rating & $8 target. Its cancer drug IPH4502 targets a huge $1.5 billion bladder cancer market.
Viking Therapeutics Stock Soars: Major Price Target Increases from Wall Street
Morgan Stanley, Cantor Fitzgerald, and BTIG raise Viking Therapeutics (VKTX) price targets to $102-$125, citing accelerated obesity trials and upcoming FDA meeting for oral treatment.
Moderna Abandons CMV Birth Defect Vaccine After Late-Stage Trial Failure
Moderna discontinues its cytomegalovirus vaccine development after Phase 3 trial shows only 6-23% efficacy, missing targets for preventing congenital birth defects in a major setback for the biotech company.
Oral VTX3232 Study Reveals Significant Reductions in Inflammatory Cardiovascular Risk Markers
Ventyx Biosciences' VTX3232 demonstrates significant reduction in heart disease risk markers in Phase 2 trial, with strong anti-inflammatory effects and good safety profile.
Molina Healthcare Cuts Full-Year Outlook After Marketplace Weakness
Molina Healthcare drastically lowered its 2025 profit outlook, blaming unexpectedly high medical costs, especially in its Marketplace (Obamacare) business.